Sign in to view content

Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study

Mark R. Barakat, MD

Video
Published 2021

Related

A Multicenter Post-Authorization Safety Study of Patients Treated With Voretigene Neparvovec-rzyl Gene Therapy in the United States: Interim Analysis at 3 Years
Aaron Nagiel, MD, PhD
Annual Meeting Talks
2024
Wet AMD 1 Symposium
Annual Meeting Talks
2020
AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 6-month Results From a Phase 1/2 Clinical Trial
Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS
Updates from the Field
2020

Category: AMD-Neovascular

See more